近日，科伦药业（Kelun Pharmaceutical）发布公告称，公司拟使用自有资金以集中竞价交易方式回购公司部分A股股份，回购金额不低于5000万元人民币，不超过1亿元人民币。此次回购的股份将用于实施员工持股计划或股权激励，旨在进一步完善公司长效激励机制，提升核心团队凝聚力与积极性，从而促进公司长期健康发展。市场分析人士指出，科伦药业当前股价处于历史相对低位，此时启动回购计划，一方面体现了公司管理层对公司内在价值的认可和对未来发展前景的信心；另一方面也有助于稳定投资者情绪、增强市场信心。此外，通过股权激励绑定核心人才，有助于公司在创新药研发、仿制药一致性评价及国际化布局等战略方向上持续推进。值得注意的是，本次回购价格不超过董事会审议通过回购方案前30个交易日公司股票交易均价的150%，具体回购数量将根据最终成交价格确定。若按上限1亿元测算，在当前股价水平下，预计可回购股份约占公司总股本的0.2%至0.4%。整体来看，此次回购举措释放了积极信号，有望对股价形成一定支撑作用。
Recently, Kelun Pharmaceutical announced its plan to repurchase a portion of its A-shares through centralized bidding transactions using its own funds, with the total repurchase amount ranging from RMB 50 million to RMB 100 million. The repurchased shares will be used for employee stock ownership plans or equity-based incentives, aiming to strengthen the company’s long-term incentive mechanisms and enhance the cohesion and motivation of its core team, thereby supporting sustainable growth.Market analysts note that Kelun’s current share price is trading near historical lows, making this an opportune time for a buyback. The move signals management’s confidence in the company’s intrinsic value and future prospects, while also helping to stabilize investor sentiment and bolster market confidence. Additionally, linking key personnel to the company’s success through equity incentives supports strategic initiatives such as innovative drug development, generic drug consistency evaluations, and international expansion.Notably, the repurchase price will not exceed 150% of the average trading price over the 30 trading days prior to the board’s approval of the repurchase plan. Depending on the final execution price, the number of shares repurchased could represent approximately 0.2% to 0.4% of the company’s total share capital. Overall, this buyback sends a positive signal and may provide underlying support to the stock price.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/8880.html